journal
MENU ▼
Read by QxMD icon Read
search

Oncologist

journal
https://www.readbyqxmd.com/read/30018134/adjuvant-subcutaneous-trastuzumab-for-her2-positive-early-breast-cancer-subgroup-analyses-of-safety-and-active-medical-conditions-by-body-weight-in-the-safeher-phase-iii-study
#1
Kyung Hae Jung, Beyhan Ataseven, Mark Verrill, Xavier Pivot, Michelino De Laurentiis, Nedal Al-Sakaff, Sabine Lauer, Mona Shing, Joseph Gligorov, Hamdy A Azim
BACKGROUND: This SafeHer subgroup analysis assessed the safety of fixed-dose subcutaneous trastuzumab (H SC) as an adjuvant therapy in HER2-positive early breast cancer (EBC) by body weight. PATIENTS AND METHODS: Patients with HER2-positive EBC not previously treated with anti-HER2 therapy received H SC 600 mg (every 3 weeks for 18 cycles), with neoadjuvant or adjuvant chemotherapy or without adjuvant chemotherapy. Adverse events (AEs) were assessed throughout treatment and at final follow-up (28 ±5 days after last treatment)...
July 17, 2018: Oncologist
https://www.readbyqxmd.com/read/30018133/selection-of-protein-kinase-inhibitors-based-on-tumor-tissue-kinase-activity-profiles-in-patients-with-refractory-solid-malignancies-an-interventional-molecular-profiling-study
#2
Mariette Labots, Johannes C Van der Mijn, Henk Dekker, Rita Ruijter, Thang V Pham, Hans J Van der Vliet, Jacobus J M Van der Hoeven, Gerrit A Meijer, Henk M W Verheul
LESSONS LEARNED: Clinically applicable tools are needed for treatment selection and repurposing of available protein kinase inhibitors (PKIs) in patients with advanced solid tumors refractory to standard treatment.Using a tyrosine kinase peptide substrate microarray, observed inhibitory activity in vitro could not sufficiently predict clinical benefit of treatment with the selected PKI. BACKGROUND: This exploratory molecular profiling study determined the feasibility and benefit of the selection of protein kinase inhibitors (PKIs) based on kinase activity profiling in patients with refractory solid malignancies...
July 17, 2018: Oncologist
https://www.readbyqxmd.com/read/30018132/a-case-of-nivolumab-induced-bullous-pemphigoid-review-of-dermatologic-toxicity-associated-with-programmed-cell-death-protein-1-programmed-death-ligand-1-inhibitors-and-recommendations-for-diagnosis-and-management
#3
Adriana T Lopez, Larisa Geskin
Immunotherapy has emerged as a highly effective treatment for numerous cancers. Use of checkpoint inhibitors against various molecules including programmed cell death protein-1 (PD-1), programmed death ligand-1 (PD-L1), and cytotoxic T-lymphocyte-associated protein-4 have become widespread in clinical practice. Compared with conventional chemotherapy, immunotherapy is associated with a unique set of immune reactions known collectively as immune-related adverse events (irAEs). Of known irAEs, cutaneous toxicity is among the most frequently observed in patients treated with immunotherapy...
July 17, 2018: Oncologist
https://www.readbyqxmd.com/read/30018131/impact-of-patient-age-on-molecular-alterations-of-left-sided-colorectal-tumors
#4
Alberto Puccini, Heinz-Josef Lenz, John L Marshall, David Arguello, Derek Raghavan, W Michael Korn, Benjamin A Weinberg, Kelsey Poorman, Arielle L Heeke, Philip A Philip, Anthony F Shields, Richard M Goldberg, Mohamed E Salem
BACKGROUND: The incidence of colorectal cancer (CRC) in younger patients is rising, mostly due to tumors in the descending colon and rectum. Therefore, we aimed to explore the molecular differences of left-sided CRC between younger (≤45 years) and older patients (≥65). SUBJECTS, MATERIALS, AND METHODS: In total, 1,126 CRC tumor samples from the splenic flexure to (and including) the rectum were examined by next-generation sequencing (NGS), immunohistochemistry, and in situ hybridization...
July 17, 2018: Oncologist
https://www.readbyqxmd.com/read/30018130/machine-learning-for-better-prognostic-stratification-and-driver-gene-identification-using-somatic-copy-number-variations-in-anaplastic-oligodendroglioma
#5
Shai Rosenberg, Francois Ducray, Agusti Alentorn, Caroline Dehais, Nabila Elarouci, Aurelie Kamoun, Yannick Marie, Marie-Laure Tanguy, Aurélien De Reynies, Karima Mokhtari, Dominique Figarella-Branger, Jean-Yves Delattre, Ahmed Idbaih
BACKGROUND: 1p/19q-codeleted anaplastic gliomas have variable clinical behavior. We have recently shown that the common 9p21.3 allelic loss is an independent prognostic factor in this tumor type. The aim of this study is to identify less frequent genomic copy number variations (CNVs) with clinical importance that may shed light on molecular oncogenesis of this tumor type. MATERIALS AND METHODS: A cohort of 197 patients with anaplastic oligodendroglioma was collected as part of the French POLA network...
July 17, 2018: Oncologist
https://www.readbyqxmd.com/read/30018129/fda-supplemental-approval-blinatumomab-for-treatment-of-relapsed-and-refractory-precursor-b-cell-acute-lymphoblastic-leukemia
#6
E Dianne Pulte, Jonathon Vallejo, Donna Przepiorka, Lei Nie, Ann T Farrell, Kirsten B Goldberg, Amy E McKee, Richard Pazdur
On July 11, 2017, the Food and Drug Administration granted approval for blinatumomab for the treatment of relapsed or refractory (R/R) precursor B-cell acute lymphoblastic leukemia (ALL). Blinatumomab is a bispecific CD19-directed CD3 T-cell engager. The basis for the approval included results from two clinical trials, TOWER and ALCANTARA. TOWER, a randomized trial comparing overall survival in patients with Philadelphia chromosome (Ph)-negative R/R ALL receiving blinatumomab versus standard-of-care (SOC) chemotherapy, demonstrated a hazard ratio of 0...
July 17, 2018: Oncologist
https://www.readbyqxmd.com/read/30012877/in-reply
#7
LETTER
Urshila Durani, Ronald S Go
No abstract text is available yet for this article.
July 16, 2018: Oncologist
https://www.readbyqxmd.com/read/30012876/disparities-in-the-use-of-programmed-death-1-immune-checkpoint-inhibitors
#8
Jeremy M O'Connor, Kathi Seidl-Rathkopf, Aracelis Z Torres, Paul You, Kenneth R Carson, Joseph S Ross, Cary P Gross
Amid growing excitement for immune checkpoint inhibitors of programmed death protein 1 (anti-PD1 agents), little is known about whether race- or sex-based disparities exist in their use. In this observational study, we constructed a large and mostly community-based cohort of patients with advanced stage cancers, including melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma, to compare the odds of receiving systemic treatment with or without anti-PD1 agents by race and by sex. In multivariable models that adjusted for age, stage, and number of prior anticancer therapies, we found no significant race-based disparities in anti-PD1 treatment...
July 16, 2018: Oncologist
https://www.readbyqxmd.com/read/30012875/seminoma-with-neoplastic-meningitis-treated-with-craniospinal-irradiation
#9
Kaylyn D Sinicrope, Alexander B Kaplan, Priscilla K Brastianos
Pure seminoma is a histological subtype of testicular cancer that accounts for 50% of testicular germ cell tumors. It has a very low rate of metastasis to the central nervous system, with only one previously reported case of neoplastic meningitis (cancer that has spread to the cerebrospinal fluid). Traditionally, neoplastic meningitis has an ominous prognosis when associated with primary tumors that commonly spread to the leptomeninges, like breast and lung. This article highlights a unique case of pure seminoma with neoplastic meningitis and illustrates the effectiveness of craniospinal irradiation as a treatment modality...
July 16, 2018: Oncologist
https://www.readbyqxmd.com/read/29959285/training-for-medical-oncologists-on-shared-decision-making-about-palliative-chemotherapy-a-randomized-controlled-trial
#10
Inge Henselmans, Hanneke W M van Laarhoven, Hanneke C J M de Haes, Meltem Tokat, Ellen G Engelhardt, Pomme E A van Maarschalkerweerd, Marleen Kunneman, Petronella B Ottevanger, Serge E Dohmen, Geert-Jan Creemers, Dirkje W Sommeijer, Filip Y F L de Vos, Ellen M A Smets
BACKGROUND: Systemic treatment for advanced cancer offers uncertain and sometimes limited benefit, while the burden can be high. This study examines the effect of shared decision-making (SDM) training for medical oncologists on observed SDM in standardized patient assessments. MATERIALS AND METHODS: A randomized controlled trial comparing training with standard practice was conducted. Medical oncologists and oncologists-in-training ( n  = 31) participated in a video-recorded, standardized patient assessment at baseline (T0) and after 4 months (T1, after training)...
June 29, 2018: Oncologist
https://www.readbyqxmd.com/read/29959284/developing-a-roadmap-for-interventional-oncology
#11
Stefan O Schoenberg, Ulrike I Attenberger, Stephen B Solomon, Ralph Weissleder
Interventional oncology uses image-guided procedures to enhance cancer care. Today, this specialty plays an increasingly critical role in cancer diagnosis (e.g., biopsy), cancer therapy (e.g., ablation or embolization), and cancer symptom palliation (e.g., nephrostomies or biliary drainages). Although the number of procedures and technical capabilities has improved over the last few years, challenges remain. In this article we discuss the need to advance existing procedures, develop new ones, and focus on several operational aspects that will dictate future interventional techniques to enhance cancer care, particularly by accelerating drug development and improving patient outcomes...
June 29, 2018: Oncologist
https://www.readbyqxmd.com/read/29959283/fear-of-mastectomy-associated-with-delayed-breast-cancer-presentation-among-ghanaian-women
#12
Yehoda M Martei, Verna Vanderpuye, Beth A Jones
BACKGROUND: Breast cancer is the leading cause of cancer mortality among women globally. Most women in Ghana present with advanced stage disease. The aim of this study is to characterize sociocultural factors associated with delayed presentation. MATERIALS AND METHODS: Qualitative study (grounded theory, constant comparative method) using individual in-depth interviews with breast cancer patients seen at the Korle Bu Teaching Hospital in Accra, Ghana. Interviews were conducted in English and three local languages...
June 29, 2018: Oncologist
https://www.readbyqxmd.com/read/29934413/brain-metastases-from-adult-sarcoma-prognostic-factors-and-impact-of-treatment-a-retrospective-analysis-from-the-french-sarcoma-group-gsf-geto
#13
Loïc Chaigneau, Anna Patrikidou, Isabelle Ray-Coquard, Thibaud Valentin, Claude Linassier, Jacques Olivier Bay, Laurence Moureau Zabotto, Emmanuelle Bompas, Sophie Piperno-Neumann, Nicolas Penel, Thierry Alcindor, Maryline Laigre, Cecile Guillemet, Sebastien Salas, Anne Hugli, Julien Domont, Marie Pierre Sunyach, Axel Lecesne, Jean Yves Blay, Virginie Nerich, Nicolas Isambert
BACKGROUND: Brain metastases (BM) from adult soft tissue or bone sarcomas are rare, and sparse data exist on their prognostic factors and management. SUBJECTS, MATERIALS AND METHODS: A retrospective study was conducted in 15 centers of the French Sarcoma Group, plus one Canadian and one Swiss center, to report on clinical, histological, and treatment characteristics and to identify predictive factors of outcome. RESULTS: Between 1992 and 2012, 246 patients with a median age of 50 years (range: 16-86) were managed for BM...
June 22, 2018: Oncologist
https://www.readbyqxmd.com/read/29934412/endocrine-therapy-in-premenopausal-hormone-receptor-positive-human-epidermal-growth-receptor-2-negative-metastatic-breast-cancer-between-guidelines-and-literature
#14
Richard Tancredi, Jenny Furlanetto, Sibylle Loibl
There is growing interest in the endocrine treatment (ET) of premenopausal women with hormone receptor positive (HR+) metastatic breast cancer (MBC). This review summarizes available data on endocrine therapy for this patient subset and aims to define the most appropriate treatment approach. The combination of luteinizing hormone-releasing hormone (LHRH) agonists plus tamoxifen seems effective and safe and is considered as being superior to either approach alone; still, single-agent therapy remains an acceptable treatment option...
June 22, 2018: Oncologist
https://www.readbyqxmd.com/read/29934411/association-of-immune-related-adverse-events-with-clinical-benefit-in-patients-with-advanced-non-small-cell-lung-cancer-treated-with-nivolumab
#15
Yukihiro Toi, Shunichi Sugawara, Yosuke Kawashima, Tomoiki Aiba, Sachiko Kawana, Ryohei Saito, Kyoji Tsurumi, Kana Suzuki, Hisashi Shimizu, Jun Sugisaka, Hirotaka Ono, Yutaka Domeki, Keisuke Terayama, Atsushi Nakamura, Shinsuke Yamanda, Yuichiro Kimura, Yoshihiro Honda
BACKGROUND: Immune-related adverse events (irAEs) are frequently observed with nivolumab monotherapy. This study aimed to evaluate whether the development of irAEs correlates with treatment response in advanced non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: We conducted a retrospective study of patients who received nivolumab monotherapy at Sendai Kousei Hospital ( n  = 70). The patients were categorized into two groups based on the incidence of irAEs: those with irAEs (irAE group) or those without (non-irAE group)...
June 22, 2018: Oncologist
https://www.readbyqxmd.com/read/29934410/barriers-and-facilitators-to-cervical-cancer-screening-diagnosis-follow-up-care-and-treatment-perspectives-of-human-immunodeficiency-virus-positive-women-and-health-care-practitioners-in-tanzania
#16
Lori Brand Bateman, Shaundra Blakemore, Alaya Koneru, Thereza Mtesigwa, Renicha McCree, Nedra F Lisovicz, Eric A Aris, Safina Yuma, Julius D Mwaiselage, Pauline E Jolly
BACKGROUND: This study was conducted to identify barriers and facilitators to cervical cancer screening, diagnosis, follow-up care, and treatment among human immunodeficiency virus (HIV)-infected women and clinicians and to explore the acceptability of patient navigators in Tanzania. MATERIALS AND METHODS: In 2012, we conducted four focus groups, two with HIV-positive women and two with clinicians who perform cervical cancer screening, diagnosis, follow-up care, and treatment...
June 22, 2018: Oncologist
https://www.readbyqxmd.com/read/29934409/cognitive-changes-after-adjuvant-treatment-in-older-adults-with-early-stage-breast-cancer
#17
Marie Lange, Natacha Heutte, Sabine Noal, Olivier Rigal, Jean-Emmanuel Kurtz, Christelle Lévy, Djelila Allouache, Chantal Rieux, Johan Lefel, Bénédicte Clarisse, Alexandra Leconte, Corinne Veyret, Philippe Barthélémy, Nadine Longato, Laure Tron, Hélène Castel, Francis Eustache, Bénédicte Giffard, Florence Joly
BACKGROUND: Group-based trajectory modeling is particularly important to identify subgroups of patients with pathological cognitive changes after cancer treatment. To date, only one study has explored cognitive trajectories in older patients with cancer. The present article describes objective cognitive changes before to after adjuvant treatment in older adults with early-stage breast cancer (EBC) after adjuvant treatment compared with healthy controls. PATIENTS AND METHODS: Participants were patients ≥65 years of age with newly diagnosed EBC and healthy controls (age-, sex-, and education-matched)...
June 22, 2018: Oncologist
https://www.readbyqxmd.com/read/29895633/reflections-on-the-boston-marathon-from-a-breast-cancer-oncologist-or-why-i-just-don-t-quit
#18
Amy H Comander
No abstract text is available yet for this article.
June 12, 2018: Oncologist
https://www.readbyqxmd.com/read/29895632/frontline-treatment-for-older-patients-with-mantle-cell-lymphoma
#19
REVIEW
Haige Ye, Aakash Desai, Dongfeng Zeng, Jorge Romaguera, Michael L Wang
The natural history of mantle cell lymphoma (MCL) undergoing chemotherapy is a cyclical pattern of remission followed by recurrence of disease due to acquired chemotherapy resistance. The median age of the occurrence of MCL is 65 years, so half of the newly diagnosed MCL patients are considered "elderly." The tolerance to long-term chemotherapy in elderly patients is decreased; hence, the response to frontline therapy used is of paramount importance. We hope that our review may guide clinicians in treating such populations in a more personalized and evidence-based manner...
June 12, 2018: Oncologist
https://www.readbyqxmd.com/read/29895631/tumor-lysis-syndrome-in-the-21st-century-to-recreate-risk-factors-and-prognosis
#20
LETTER
François Vincent, Michael Darmon
No abstract text is available yet for this article.
June 12, 2018: Oncologist
journal
journal
20207
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"